Oncology Medical News about Uterine Cervical Neoplasms Vaginal Neoplasms Vulvar Neoplasms human papillomavirus vaccine L1, type 6,11,16,18

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
International Journal of Women's Health, 09/17/09

Diaz ML – The prevalence of oncogenic HPV subtypes in cervical cancers has been the most studied, but prevalence has also been established for vaginal and vulvar cancers. Clinical trials demonstrate impressive efficacy in disease prevention as well as excellent safety and tolerability. The role the quadrivalent HPV recombinant vaccine promises to have in the reduction of gynecologic malignancies will depend on various factors, including acceptance and accessibility of the vaccine, duration of immunity, and cross–protection against other oncogenic HPV subtypes. The HPV vaccine’s role in disease reduction will probably be viewed in the context of a strategy that involves continued secondary screening and lifestyle modification to reduce modifiable risk factors, along with widespread vaccination.

<< Previous
Comorbidity, disability and geriatric syndromes in elderly breast...

Next >>
Human leukocyte antigen class I expression is an independent...